R289

· Rigel Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for R289, covering 2025-10-21 to 2025-10-21. Get the full timeline:

Most recent: Clinical Trial Update: Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) [Phase 1, Phase 2]